Esophagogastric Tumors
Showing 1 - 25 of >10,000
Esophagogastric Tumors, Gastric Cancer, Gastric Tumor Trial in United States (Trastuzumab, Pembrolizumab)
Recruiting
- Esophagogastric Tumors
- +9 more
-
Basking Ridge, New Jersey
- +6 more
Jul 8, 2022
Esophageal Cancer, Gastric Adenocarcinoma, HER2 Gene Mutation Trial in United States (Pembrolizumab, Trastuzumab)
Not yet recruiting
- Esophageal Cancer
- +2 more
-
Baltimore, Maryland
- +8 more
Nov 3, 2023
Advanced Solid Tumors, Gastric Cancer, Esophagogastric Junction Cancer Trial in Beijing (IM92 CAR-T cells)
Recruiting
- Advanced Solid Tumors
- +3 more
- IM92 CAR-T cells
-
Beijing, Beijing, ChinaChinese PLA GENERAL HOSPITAL
Mar 10, 2022
Endometrial Cancer, Esophageal Cancer, Esophagogastric Junction (EGJ) Trial in Worldwide (Autologous genetically modified
Recruiting
- Endometrial Cancer
- +8 more
- Autologous genetically modified ADP-A2M4CD8 cells alone or in combination with nivolumab every four weeks or pembrolizumab every 6 weeks
-
Orlando, Florida
- +21 more
Feb 2, 2023
HER2-positive, Adenocarcinoma, Bile Duct Cancer Trial in United States (CT-0508)
Recruiting
- HER2-positive
- +30 more
- CT-0508
-
Duarte, California
- +4 more
Feb 1, 2022
Basal Cell Carcinoma, Medulloblastoma, Adenocarcinoma of Esophagogastric Junction Trial in Chang Chun (ZSP1602)
Recruiting
- Basal Cell Carcinoma
- +5 more
-
Chang Chun, Jilin, ChinaJilin Cancer Hospital
Jul 20, 2020
Esophagogastric Cancer Trial in Toronto (PET-MRI)
Recruiting
- Esophagogastric Cancer
- PET-MRI
-
Toronto, Ontario, CanadaPrincess Margaret Cancer Centre
Apr 5, 2023
B Cell Lymphoma, B Cell Leukemia, Myeloma Trial in Wenzhou (CAR-CD19 T cell, CAR-BCMA T cell, CAR-GPC3 T cell)
Active, not recruiting
- B Cell Lymphoma
- +5 more
- CAR-CD19 T cell
- +5 more
-
Wenzhou, Zhejiang, ChinaFirst Affiliated Hospital of Wenzhou Medical University
Oct 5, 2020
Advanced Digestive System Tumor Trial in China (IMC001 injection)
Not yet recruiting
- Advanced Digestive System Tumor
- IMC001 injection
-
Beijing, Beijing, China
- +6 more
Jul 12, 2023
Neoadjuvant Chemotherapy and Immunotherapy for HER2(-),pMMR
Recruiting
- Gastric Cancer
- SOX plus Paclitaxel(albumin-bound) followed by PD-1 antibody
-
Beijing, Beijing, ChinaNational Cancer Center/National Clinical Research Center for Can
Sep 12, 2022
Siewert Type II Adenocarcinoma of Esophagogastric Junction Trial in Xi'an (Endoscopy Ivor-lewis, Laparoscopic transabdominal
Recruiting
- Siewert Type II Adenocarcinoma of Esophagogastric Junction
- Endoscopy Ivor-lewis
- Laparoscopic transabdominal enlarged gastrectomy
-
Xi'an, Shaanxi, ChinaLi
Jun 7, 2022
Adenocarcinoma of Esophagogastric Junction Trial in Beijing (neoadjuvant Radiation plus SOX and PD-1 antibody)
Not yet recruiting
- Adenocarcinoma of Esophagogastric Junction
- neoadjuvant Radiation plus SOX and PD-1 antibody
-
Beijing, Beijing, ChinaPeking University People's Hospital
Aug 15, 2022
Stomach Tumors Trial in Shanghai (Fruquintinib, Sintilimab)
Active, not recruiting
- Stomach Neoplasms
-
Shanghai, ChinaRenji Hospital
Apr 3, 2023
Gastric Tumor, Gastroesophageal Junction Adenocarcinoma, Esophageal Adenocarcinoma Trial in Dresden, Heidelberg (Biopsy)
Active, not recruiting
- Gastric Neoplasm
- +4 more
- Biopsy
-
Dresden, Germany
- +1 more
Feb 22, 2022
Esophageal Cancer, Gastric Cancer Trial in United States (Afatinib and Paclitaxel)
Active, not recruiting
- Esophageal Cancer
- Gastric Cancer
- Afatinib and Paclitaxel
-
Los Angeles, California
- +8 more
Mar 18, 2022
Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial (pembrolizumab)
Completed
- Esophageal Carcinoma
- Esophagogastric Junction Carcinoma
- pembrolizumab
- (no location specified)
Aug 18, 2022
Gastric Cancer, Colorectal Cancer, Pancreatic Cancer Trial in Pittsburgh (Tumor Infiltrating Lymphocytes (TIL), Fludarabine +
Recruiting
- Gastric Cancer
- +9 more
- Tumor Infiltrating Lymphocytes (TIL)
- Fludarabine + Cyclophosphamide combination
-
Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center
Jul 21, 2022
Gastric Cancer Trial (OGT group, Overlap group)
Recruiting
- Gastric Cancer
- OGT group
- Overlap group
-
Guangzhou, Guangdong, ChinaXinhua Chen
Nov 2, 2022
Esophagus Cancer, Gastric Cancer, Leak, Anastomotic Trial in Valencia (audit of complications, prospective data collection)
Enrolling by invitation
- Esophagus Cancer
- +3 more
- audit of complications, prospective data collection
-
Valencia, SpainMarcos Bruna
May 19, 2022
Pancreatic Cancer, NSCLC, Esophagogastric Cancer Trial in United States (Andecaliximab, Gemcitabine, Nab-paclitaxel)
Completed
- Pancreatic Cancer
- +4 more
- Andecaliximab
- +10 more
-
Birmingham, Alabama
- +17 more
May 20, 2020
Gastric Cancer Trial in Beijing (Radical gastrectomy with dissection of lower mediastinal lymph node)
Recruiting
- Gastric Cancer
- Radical gastrectomy with dissection of lower mediastinal lymph node
-
Beijing, Beijing, ChinaBeijing Cancer Hospital
Nov 21, 2021
Gastric, Colorectal Adenocarcinoma Trial in Shenyang (tislelizumab)
Not yet recruiting
- Gastric
- Colorectal Adenocarcinoma
-
Shenyang, Liaoning, ChinaLiaoning Cancer Hospital & Institute
Nov 1, 2023
Esophageal Carcinoma, Esophagogastric Junction Carcinoma Trial in China (pembrolizumab, paclitaxel, docetaxel)
Completed
- Esophageal Carcinoma
- Esophagogastric Junction Carcinoma
- pembrolizumab
- +3 more
-
Hefei, Anhui, China
- +22 more
Aug 16, 2022